3 results
To determine non inferiority of two doses of BI 10773 (10 mg/daily and 25 mg/daily) compared to placebo with respect to first occurrence of any of the adjudicated components of the primary composite Major Adverse Cardiovascular Event endpoint (…
To date, non-clinical and clinical data have been generated to support further investigation of RO7234292 in patients with early manifest HD. Building on the recently completed Phase I/IIa study and the ongoing OLE study, this Phase Ia study (…
This study has two parts. The purpose of the first part of the study is to investigate if the investigational drug called dostarlimab (also known as TSR-042) in combination with standard chemotherapy (carboplatin and paclitaxel) will improve the…